Metformin is the diabetes medication most likely to cause both metabolic acidosis and hyperkalemia
Metformin causes lactic acidosis (a form of metabolic acidosis) and can lead to hyperkalemia, particularly in patients with acute kidney injury or chronic kidney disease. 1
Why Metformin Causes These Complications
Metformin accumulates in patients with impaired kidney function, leading to metformin-associated lactic acidosis (MALA). When metformin levels become toxic (therapeutic range <5 mcg/mL), patients develop:
- Severe lactic acidosis - the hallmark metabolic acidosis associated with metformin toxicity 2
- Refractory hyperkalemia - a rare but serious manifestation requiring multiple interventions, sometimes even continuous renal replacement therapy 1
The mechanism involves metformin accumulation when clearance is impaired (renal dysfunction) or when lactic acid clearance is compromised (liver failure), combined with conditions causing anaerobic metabolism (sepsis, hypoxia, shock) 2.
High-Risk Clinical Scenarios
Metformin should be avoided or discontinued in patients with 2:
- eGFR <30 mL/min per 1.73 m² (absolute contraindication)
- eGFR 30-45 mL/min per 1.73 m² (dose reduction required)
- Acute kidney injury
- Hypoxia or shock states
- Liver disease or alcoholism
- Acute heart failure
- Before iodinated contrast procedures (if eGFR <60 mL/min per 1.73 m²)
A recent study of over 1,200 patients with type 2 diabetes and COVID-19 found inpatient metformin use increased lactic acidosis risk significantly (adjusted hazard ratio 4.46,95% CI 1.11–18.0), with higher risk associated with higher doses, worse kidney function, and greater illness severity 2.
Important Distinction: SGLT2 Inhibitors Cause Acidosis BUT NOT Hyperkalemia
While SGLT2 inhibitors cause euglycemic diabetic ketoacidosis (a different type of metabolic acidosis), they actually reduce hyperkalemia risk rather than increase it 3. In fact, SGLT2 inhibitors show minimal effect on blood pressure and no excess risk of hyperkalemia, distinguishing them from other diabetes medications 4. A 2025 study found SGLT2 inhibitors were associated with a lower risk of hyperkalemia compared to DPP-4 inhibitors (hazard ratio 0.74) 3, and another 2025 study found no clinically significant changes in potassium levels with SGLT2 inhibitor therapy 5.
Clinical Bottom Line
When you see the combination of metabolic acidosis AND hyperkalemia in a diabetic patient, think metformin toxicity first, especially if the patient has any degree of kidney impairment or acute illness. Check metformin levels, lactate, and kidney function immediately, and discontinue the medication 1.